Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1990 1
2002 2
2003 1
2005 2
2006 1
2008 3
2009 1
2010 3
2011 5
2012 4
2014 2
2015 5
2016 7
2017 2
2018 5
2019 6
2020 8
2021 6
2022 8
2023 9
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

75 results

Results by year

Filters applied: . Clear all
Page 1
First-line diuretics versus other classes of antihypertensive drugs for hypertension.
Reinhart M, Puil L, Salzwedel DM, Wright JM. Reinhart M, et al. Cochrane Database Syst Rev. 2023 Jul 13;7(7):CD008161. doi: 10.1002/14651858.CD008161.pub3. Cochrane Database Syst Rev. 2023. PMID: 37439548 Review.
MAIN RESULTS: We included 20 trials with 26 comparator arms randomizing over 90,000 participants. The findings are relevant to first-line use of drug classes in older male and female hypertensive patients (aged 50 to 75) with multiple co-morbidities, including type …
MAIN RESULTS: We included 20 trials with 26 comparator arms randomizing over 90,000 participants. The findings are relevant to first-line …
Interventions for acne scars.
Abdel Hay R, Shalaby K, Zaher H, Hafez V, Chi CC, Dimitri S, Nabhan AF, Layton AM. Abdel Hay R, et al. Cochrane Database Syst Rev. 2016 Apr 3;4(4):CD011946. doi: 10.1002/14651858.CD011946.pub2. Cochrane Database Syst Rev. 2016. PMID: 27038134 Free PMC article. Review.
Nine studies provided no usable data on our outcomes and did not contribute further to this review's results.For our outcome 'Participant-reported scar improvement' in one study fractional laser was more effective in producing scar improvement than non-fractional non-ablative las …
Nine studies provided no usable data on our outcomes and did not contribute further to this review's results.For our outcome 'Participant-re …
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP. Gilbert MR, et al. N Engl J Med. 2014 Feb 20;370(8):699-708. doi: 10.1056/NEJMoa1308573. N Engl J Med. 2014. PMID: 24552317 Free PMC article. Clinical Trial.
There was no significant difference in the duration of overall survival between the bevacizumab group and the placebo group (median, 15.7 and 16.1 months, respectively; hazard ratio for death in the bevacizumab group, 1.13). Progression-free survival was longer in the beva …
There was no significant difference in the duration of overall survival between the bevacizumab group and the placebo group (median, 15.7 an …
Cost-effectiveness of first-line versus second-line use of domestic anti-PD-1 antibody sintilimab in Chinese patients with advanced or metastatic squamous non-small cell lung cancer.
Cheng R, Zhou Z, Liu Q. Cheng R, et al. Cancer Med. 2023 Mar;12(6):7389-7397. doi: 10.1002/cam4.5440. Epub 2022 Nov 13. Cancer Med. 2023. PMID: 36373001 Free PMC article.
. $14,045) compared with the first-line sintilimab, resulting in an incremental cost-effectiveness ratio (ICER) of $12,693 per QALY. The results of DSA suggested that variations in all parameters did not result in the ICERs surpassing the willingness-to-pay threshold of $3 …
. $14,045) compared with the first-line sintilimab, resulting in an incremental cost-effectiveness ratio (ICER) of $12,693 per QALY. …
First-line versus second-line use of pralsetinib in treatment of rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer: a cost-effectiveness analysis.
Liu W, Huo G, Li M, Chen P. Liu W, et al. Transl Lung Cancer Res. 2023 Sep 28;12(9):1949-1958. doi: 10.21037/tlcr-23-469. Epub 2023 Sep 21. Transl Lung Cancer Res. 2023. PMID: 37854153 Free PMC article.
The primary endpoints included quality-adjusted life years (QALYs), lifetime costs, and incremental cost-effectiveness ratio (ICER). RESULTS: Compared to chemotherapy, the use of PRL in the first-line therapy resulted in an additional 0.07 QALYs at a cost of $133,561, with …
The primary endpoints included quality-adjusted life years (QALYs), lifetime costs, and incremental cost-effectiveness ratio (ICER). …
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma.
Dummer R, Long GV, Robert C, Tawbi HA, Flaherty KT, Ascierto PA, Nathan PD, Rutkowski P, Leonov O, Dutriaux C, Mandalà M, Lorigan P, Ferrucci PF, Grob JJ, Meyer N, Gogas H, Stroyakovskiy D, Arance A, Brase JC, Green S, Haas T, Masood A, Gasal E, Ribas A, Schadendorf D. Dummer R, et al. J Clin Oncol. 2022 May 1;40(13):1428-1438. doi: 10.1200/JCO.21.01601. Epub 2022 Jan 14. J Clin Oncol. 2022. PMID: 35030011 Free PMC article. Clinical Trial.
RESULTS: At data cutoff (July 1, 2020), the median progression-free survival was 16.2 months (95% CI, 12.7 to 23.9 months) in the sparta-DabTram arm versus 12.0 months (95% CI, 10.2 to 15.4 months) in the placebo-DabTram arm (hazard ratio, 0.82 [95% CI, 0.66 to 1.03]; P = …
RESULTS: At data cutoff (July 1, 2020), the median progression-free survival was 16.2 months (95% CI, 12.7 to 23.9 months) in the sparta-Dab …
Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma.
Patel KK, Giri S, Parker TL, Bar N, Neparidze N, Huntington SF. Patel KK, et al. J Clin Oncol. 2021 Apr 1;39(10):1119-1128. doi: 10.1200/JCO.20.01849. Epub 2021 Jan 7. J Clin Oncol. 2021. PMID: 33411586 Clinical Trial.
Lifetime direct healthcare costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs) were calculated for first-line daratumumab versus second-line daratumumab from a US payer perspective. ...
Lifetime direct healthcare costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs) were calcula …
Real-World First-Line Use of Pertuzumab With Different Taxanes for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Comparative Effectiveness Study Using US Electronic Health Records.
Polito L, Shim J, Hurvitz SA, Dang CT, Knott A, Du Toit Y, Restuccia E, Sanglier T, Swain SM. Polito L, et al. JCO Oncol Pract. 2023 Jul;19(7):435-445. doi: 10.1200/OP.22.00565. Epub 2023 May 11. JCO Oncol Pract. 2023. PMID: 37167571 Free PMC article.
After adjustment for potential confounders, similar median rwPFS (inverse probability of treatment weighted average treatment effect for the treated [IPTW-ATT] hazard ratio [HR], 1.09; 95% CI, 0.9 to 1.3; P = .365) and rwOS (IPTW-ATT HR, 1.23; 95% CI, 0.96 to 1.58; P = .10 …
After adjustment for potential confounders, similar median rwPFS (inverse probability of treatment weighted average treatment effect for the …
Daratumumab in first-line therapy is cost-effective in transplant-eligible patients with newly diagnosed myeloma.
Yamamoto C, Minakata D, Koyama S, Sekiguchi K, Fukui Y, Murahashi R, Nakashima H, Matsuoka S, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Nagayama T, Umino K, Nakano H, Morita K, Yamasaki R, Ashizawa M, Ueda M, Hatano K, Sato K, Ohmine K, Fujiwara SI, Kanda Y. Yamamoto C, et al. Blood. 2022 Aug 11;140(6):594-607. doi: 10.1182/blood.2021015220. Blood. 2022. PMID: 35580269 Free PMC article.
In this study, we conducted a cost-effectiveness analysis with a 10-year time horizon to compare first-line and second-line use of daratumumab for transplant-eligible patients with NDMM. ...Quality-adjusted life-years (QALYs) and incremental cost-effectiveness ra …
In this study, we conducted a cost-effectiveness analysis with a 10-year time horizon to compare first-line and second-line use …
Cost-effectiveness analysis of selective first-line use of biologics for unresectable RAS wild-type left-sided metastatic colorectal cancer.
Wong WWL, Zargar M, Berry SR, Ko YJ, Riesco-Martínez M, Chan KKW. Wong WWL, et al. Curr Oncol. 2019 Oct;26(5):e597-e609. doi: 10.3747/co.26.4843. Epub 2019 Oct 1. Curr Oncol. 2019. PMID: 31708653 Free PMC article.
In the present study, we aimed to determine the incremental cost-effectiveness ratio (icer) for the first-line use of an egfri for patients with left-sided wtRAS mcrc. ...
In the present study, we aimed to determine the incremental cost-effectiveness ratio (icer) for the first-line use of a …
75 results